{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:23:17Z","timestamp":1786980197788,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>In ovarian cancer, there are two main routes of metastasis, namely intraperitoneal and retroperitoneal. Their biologic background is poorly understood. Identifying molecular markers involved might enable the development of tailored therapy regimens. Moreover, no reliable markers for response to anti-angiogenic treatment with bevacizumab are yet established. Angiopoietin-2 (Ang-2) is an angiogenic growth factor, involved in lymphatic activation and is associated with tumor progression. Here, we assessed the potential of Ang-2 as a molecular marker in metastasis and treatment of ovarian cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In our study, quantitative and qualitative protein Ang-2 expression in tumor tissue of ovarian cancer patients was analyzed by Western blot (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009138) and immunohistochemistry (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200958). Further, Ang-2 levels in blood samples were quantified in enzyme-linked immunosorbent assay (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200938). Expression levels of different tumor spread patterns were evaluated, and survival analyses were made.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We observed that Ang-2 expression is significantly higher in tumors with retroperitoneal dissemination (pT1a\u2013pT3b, pN1) compared to those showing intraperitoneal tumor growth (pT3c, pN0). In addition, patients with high Ang-2 expression have significantly longer overall survival compared to patients with low Ang-2 expression. Patients with high Ang-2 expression benefit significantly from therapy with bevacizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>All in all, Ang-2 may serve as a molecular marker for patients with tumors prone to spread to lymph nodes and for patients who might benefit from bevacizumab therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-023-05354-1","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T12:16:09Z","timestamp":1694175369000},"page":"15957-15967","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ang-2 is a potential molecular marker for lymphatic metastasis and better response to bevacizumab therapy in ovarian cancer"],"prefix":"10.1007","volume":"149","author":[{"given":"Annabelle","family":"Volk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Legler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Hamester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Kuerti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Eylmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maila","family":"Rossberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Schmalfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Oliveira-Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"5354_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3390\/cells8050471","volume":"8","author":"RG Akwii","year":"2019","unstructured":"Akwii RG, Sajib MS, Zahra FT, Mikelis CM (2019) Role of Angiopoietin-2 in vascular physiology and pathophysiology. Cells 8:471","journal-title":"Cells"},{"key":"5354_CR2","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1158\/1078-0432.CCR-19-0226","volume":"26","author":"A Alvarez Secord","year":"2020","unstructured":"Alvarez Secord A, Bell Burdett K, Owzar K, Tritchler D, Sibley AB, Liu Y, Starr MD, Brady JC, Lankes HA, Hurwitz HI, Mannel RS, Tewari KS, O\u2019Malley DM, Gray H, Bakkum-Gamez JN, Fujiwara K, Boente M, Deng W, Burger RA, Birrer MJ, Nixon AB (2020) Predictive blood-based biomarkers in patients with epithelial ovarian cancer treated with carboplatin and paclitaxel with or without bevacizumab: results from GOG-0218. Clin Cancer Res 26:1288\u20131296","journal-title":"Clin Cancer Res"},{"key":"5354_CR3","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473\u20132483","journal-title":"N Engl J Med"},{"key":"5354_CR4","doi-asserted-by":"publisher","first-page":"6979","DOI":"10.3748\/wjg.v19.i41.6979","volume":"19","author":"F Coccolini","year":"2013","unstructured":"Coccolini F, Gheza F, Lotti M, Virz\u00ec S, Iusco D, Ghermandi C, Melotti R, Baiocchi G, Giulini SM, Ansaloni L, Catena F (2013) Peritoneal carcinomatosis. World J Gastroenterol 19:6979\u20136994","journal-title":"World J Gastroenterol"},{"key":"5354_CR5","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/annonc\/mdz062","volume":"30","author":"N Colombo","year":"2019","unstructured":"Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I, Dashora A, Olbrecht S, Planchamp F, Querleu D (2019) ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease\u2020. Ann Oncol 30:672\u2013705","journal-title":"Ann Oncol"},{"key":"5354_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ydbio.2008.04.024","volume":"319","author":"M Dellinger","year":"2008","unstructured":"Dellinger M, Hunter R, Bernas M, Gale N, Yancopoulos G, Erickson R, Witte M (2008) Defective remodeling and maturation of the lymphatic vasculature in Angiopoietin-2 deficient mice. Dev Biol 319:309\u2013320","journal-title":"Dev Biol"},{"key":"5354_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269680","volume":"17","author":"Y Ding","year":"2022","unstructured":"Ding Y, Oliveira-Ferrer L, Vettorazzi E, Legler K, Milde-Langosch K, Woelber L, Jaeger A, Prieske K, Mueller V, Schmalfeldt B, Kuerti S (2022) VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients. PLoS\u00a0One 17:e0269680","journal-title":"PLoS\u00a0One"},{"key":"5354_CR8","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/sj.bjc.6605925","volume":"103","author":"V Goede","year":"2010","unstructured":"Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC, Weihrauch MR, Cremer B, Kashkar H, Odenthal M, Augustin HG, Schmiegel W, Hallek M, Hacker UT (2010) Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer 103:1407\u20131414","journal-title":"Br J Cancer"},{"key":"5354_CR9","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMoa1808424","volume":"380","author":"P Harter","year":"2019","unstructured":"Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, Kim JW, Raspagliesi F, Lampe B, Aletti G, Meier W, Cibula D, Mustea A, Mahner S, Runnebaum IB, Schmalfeldt B, Burges A, Kimmig R, Scambia G, Greggi S, Hilpert F, Hasenburg A, Hillemanns P, Giorda G, von Leffern I, Schade-Brittinger C, Wagner U, du Bois A (2019) A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med 380:822\u2013832","journal-title":"N Engl J Med"},{"key":"5354_CR10","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1158\/0008-5472.CAN-09-1977","volume":"70","author":"H Hashizume","year":"2010","unstructured":"Hashizume H, Falc\u00f3n BL, Kuroda T, Baluk P, Coxon A, Yu D, Bready JV, Oliner JD, McDonald DM (2010) Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 70:2213\u20132223","journal-title":"Cancer Res"},{"key":"5354_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2217\/fon-2019-0042","volume":"16","author":"CE Haunschild","year":"2020","unstructured":"Haunschild CE, Tewari KS (2020) Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer. Future Oncol 16:225\u2013246","journal-title":"Future Oncol"},{"key":"5354_CR12","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/jnci\/djs009","volume":"104","author":"T Holopainen","year":"2012","unstructured":"Holopainen T, Saharinen P, D\u2019Amico G, Lampinen A, Eklund L, Sormunen R, Anisimov A, Zarkada G, Lohela M, Heloter\u00e4 H, Tammela T, Benjamin LE, Yl\u00e4-Herttuala S, Leow CC, Koh GY, Alitalo K (2012) Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J Natl Cancer Inst 104:461\u2013475","journal-title":"J Natl Cancer Inst"},{"key":"5354_CR13","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1200\/JCO.2014.56.3106","volume":"33","author":"NS Horowitz","year":"2015","unstructured":"Horowitz NS, Miller A, Rungruang B, Richard SD, Rodriguez N, Bookman MA, Hamilton CA, Krivak TC, Maxwell GL (2015) Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J Clin Oncol 33:937\u2013943","journal-title":"J Clin Oncol"},{"key":"5354_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3322\/caac.20113","volume":"61","author":"D Jelovac","year":"2011","unstructured":"Jelovac D, Armstrong DK (2011) Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 61:183\u2013203","journal-title":"CA Cancer J Clin"},{"key":"5354_CR15","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1245\/s10434-009-0474-9","volume":"16","author":"MJ Jo","year":"2009","unstructured":"Jo MJ, Lee JH, Nam BH, Kook MC, Ryu KW, Choi IJ, Kim YW, Bae JM (2009) Preoperative serum angiopoietin-2 levels correlate with lymph node status in patients with early gastric cancer. Ann Surg Oncol 16:2052\u20132057","journal-title":"Ann Surg Oncol"},{"key":"5354_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1365-2362.2006.01602.x","volume":"36","author":"IE Koutroubakis","year":"2006","unstructured":"Koutroubakis IE, Xidakis C, Karmiris K, Sfiridaki A, Kandidaki E, Kouroumalis EA (2006) Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease. Eur J Clin Investig 36:127\u2013132","journal-title":"Eur J Clin Investig"},{"key":"5354_CR17","doi-asserted-by":"publisher","first-page":"43218","DOI":"10.18632\/oncotarget.17978","volume":"8","author":"S Kuerti","year":"2017","unstructured":"Kuerti S, Oliveira-Ferrer L, Milde-Langosch K, Schmalfeldt B, Legler K, Woelber L, Prieske K, Mahner S, Trillsch F (2017) VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients. Oncotarget 8:43218\u201343227","journal-title":"Oncotarget"},{"key":"5354_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3773","volume":"371","author":"L Kuroki","year":"2020","unstructured":"Kuroki L, Guntupalli SR (2020) Treatment of epithelial ovarian cancer. BMJ 371:m3773","journal-title":"BMJ"},{"key":"5354_CR19","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1038\/sj.bjc.6602655","volume":"92","author":"K Milde-Langosch","year":"2005","unstructured":"Milde-Langosch K, Bamberger AM, Rieck G, Grund D, Hemminger G, M\u00fcller V, L\u00f6ning T (2005) Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1\/2) in breast cancer. Br J Cancer 92:2206\u20132215","journal-title":"Br J Cancer"},{"key":"5354_CR20","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S1470-2045(14)70244-X","volume":"15","author":"BJ Monk","year":"2014","unstructured":"Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhomm\u00e9 C, Richardson G, Rinc\u00f3n DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM (2014) Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15:799\u2013808","journal-title":"Lancet Oncol"},{"key":"5354_CR21","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1365-2796.2005.01550.x","volume":"258","author":"SK Nadar","year":"2005","unstructured":"Nadar SK, Blann A, Beevers DG, Lip GY (2005) Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)]. J Intern Med 258:336\u2013343","journal-title":"J Intern Med"},{"key":"5354_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.117080","volume":"239","author":"G Nicolini","year":"2019","unstructured":"Nicolini G, Forini F, Kusmic C, Iervasi G, Balzan S (2019) Angiopoietin 2 signal complexity in cardiovascular disease and cancer. Life Sci 239:117080","journal-title":"Life Sci"},{"key":"5354_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2014.05.002","volume":"26","author":"S Pradeep","year":"2014","unstructured":"Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, Pecot CV, Kim SJ, Choi HJ, Bischoff FZ, Mayer JA, Huang L, Nick AM, Hall CS, Rodriguez-Aguayo C, Zand B, Dalton HJ, Arumugam T, Lee HJ, Han HD, Cho MS, Rupaimoole R, Mangala LS, Sehgal V, Oh SC, Liu J, Lee JS, Coleman RL, Ram P, Lopez-Berestein G, Fidler IJ, Sood AK (2014) Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell 26:77\u201391","journal-title":"Cancer Cell"},{"key":"5354_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3802\/jgo.2015.26.2.87","volume":"26","author":"J Prat","year":"2015","unstructured":"Prat J (2015) FIGO\u2019s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol 26:87\u201389","journal-title":"J Gynecol Oncol"},{"key":"5354_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-540-78281-0_2","volume":"180","author":"Y Reiss","year":"2010","unstructured":"Reiss Y (2010) Angiopoietins. Recent Results Cancer Res 180:3\u201313","journal-title":"Recent Results Cancer Res"},{"key":"5354_CR26","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/1097-0142(19891001)64:7<1508::AID-CNCR2820640725>3.0.CO;2-V","volume":"64","author":"PG Rose","year":"1989","unstructured":"Rose PG, Piver MS, Tsukada Y, Lau TS (1989) Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. Cancer 64:1508\u20131513","journal-title":"Cancer"},{"key":"5354_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/bjc.2015.436","volume":"114","author":"F Trillsch","year":"2016","unstructured":"Trillsch F, Kuerti S, Eulenburg C, Burandt E, Woelber L, Prieske K, Eylmann K, Oliveira-Ferrer L, Milde-Langosch K, Mahner S (2016) E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer. Br J Cancer 114:213\u2013220","journal-title":"Br J Cancer"},{"key":"5354_CR28","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/S1470-2045(19)30178-0","volume":"20","author":"I Vergote","year":"2019","unstructured":"Vergote I, Scambia G, O\u2019Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ (2019) Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3\/ENGOT-ov2\/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet Oncol 20:862\u2013876","journal-title":"Lancet Oncol"},{"key":"5354_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008063","volume":"96","author":"Y Xu","year":"2017","unstructured":"Xu Y, Zhang Y, Wang Z, Chen N, Zhou J, Liu L (2017) The role of serum angiopoietin-2 levels in progression and prognosis of lung cancer: a meta-analysis. Medicine (baltimore) 96:e8063","journal-title":"Medicine (baltimore)"},{"key":"5354_CR30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s13402-020-00513-9","volume":"43","author":"M Yousefi","year":"2020","unstructured":"Yousefi M, Dehghani S, Nosrati R, Ghanei M, Salmaninejad A, Rajaie S, Hasanzadeh M, Pasdar A (2020) Current insights into the metastasis of epithelial ovarian cancer\u2014hopes and hurdles. Cell Oncol (dordr) 43:515\u2013538","journal-title":"Cell Oncol (dordr)"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-05354-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T01:25:25Z","timestamp":1698801925000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-05354-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":30,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["5354"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-05354-1","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]},"assertion":[{"value":"29 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest concerning the presented analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients gave written informed consent to gain biomaterial and view their clinical records. This was approved by the local ethics committee \u201cEthik-Kommission der \u00c4rztekammer Hamburg\u201d (no. 04.05.2004). All methods were performed in accordance with the relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}